



ABN 82 010 975 612

PO Box 2403 Toowong  
Queensland 4066 Australia  
Telephone: + 61 7 3842 3333  
Facsimile: + 61 7 3720 9624  
[www.progen-pharma.com](http://www.progen-pharma.com)

## **Progen Pharmaceuticals Patent granted in important Japanese market**

**Brisbane, Australia, 28th June 2010.** The Directors of Progen Pharmaceuticals Limited (ASX:PGL, NASDAQ:PGLA) today announced the granting of a Japanese patent for the Preparation and Use of Sulfated Oligosaccharides which includes muparfostat (PI-88).

Progen Pharmaceuticals Limited has an exclusive worldwide license to muparfostat (PI-88) technology from the Australian National University.

"Japan is an important market for liver cancer and the granting of this patent provides additional coverage in this key territory," said Sue MacLeman, Chief Executive Officer, Progen Pharmaceuticals Ltd.

PI-88 is one of a class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumour activity is based on inhibition of two biological processes – angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) – critical to the growth and progression of cancer.

The patent number is 4514240. The applicant for the patent is the Australian National University. The date of grant was 21<sup>st</sup> May 2010 and the patent term is 20 years from April 24<sup>th</sup> 1996 (date of commencement of patent term), expiring 24<sup>th</sup> April 2016.

Historically, PI-88 was the result of fully funded research collaboration with Professor Chris Parish's group at the John Curtin School of Medical Research at The Australian National University.

**ENDS**

### **About Progen Pharmaceuticals Ltd**

Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. Progen has operations in Australia and the United States of America. [www.progen-pharma.com](http://www.progen-pharma.com)

#### **For more information:**

Sue MacLeman  
Chief Executive Officer  
+61 7 3842 3333  
+61 437 211 200

Jo-Anne Modesti  
Phillips Group  
+61 7 3230 5000

This release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by, amongst others, the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PG11047, PG545, PG562, PG11122, PG11144 and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.